Search Browse Earnings

Altimmune, Inc.

Nasdaq:ALT

Pharmaceutical Preparations·GAITHERSBURG, MD

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Altimmune, Inc. — SlamSEC

Revenue

$8.2M

+41.1% YoY

FY 2021

Adj. EBITDA

-$102.7M

-1255.3% margin

FY 2025

Net Income

-$95.1M

-1161.4% margin

FY 2025

EPS (Diluted)

-$1.34

FY 2025

Stock Price

$3.87

+9.3%

2026-03-09

52W Range

$2.90 – $7.73

P/E Ratio

-2.9x

Market Cap

$503.4M

Cash

$36.9M

FY 2025

Total Debt

$35.4M

FY 2025

Net Cash

$1.5M

FY 2025

Enterprise Value

$501.8M

Debt / EBITDA

0.0x

FY 2021

EV / EBITDA

-4.9x

Employees

—